Life Sciences Archive » October, 2014

Life Sciences - October, 2014

302 articles

• Herbalife Pays $15M To End 'Pyramid Scheme' Class Action
• 11th Circ. Rejects ERISA Claim Against Stiefel Labs
• Pfizer Ducks End-Payors' Lipitor Antitrust Claims
• AstraZeneca Slams Actavis With IP Suit Over Diabetes Drug
• 4 Cos. Raise $1.2B As US IPO Market Warms Back Up
• Sanofi's Duty To Detail FDA Concerns Key To Lemtrada Cases
• HHS Watchdog Details 2015 Plans To Scrutinize Medical Billing
• Consumer Group Takes Stem Cell Patent Fight To High Court
• 7th Circ. Casts A Wary Eye On Supplement Labeling Deal
• Actavis, NY AG Spar Over Antitrust Suit Injunction Bid
• Atossa Beats Claims It Duped Investors In $4M Offering
• 8 Ballot Measures Attorneys Will Be Watching
• Recall Or Enhancement? Read These Medical Device Rules
• Eli Lilly, Takeda Plan Appeal Of $37M Actos Ruling
• BMS, Sanofi Get Gene Patent Partially Invalidated In IP Suit
• Insurer On The Hook For Stryker Defect Claims, Judge Rules
• Merck Unit Says Fed. Circ. Erred In AllPure Patent Ruling
• SEC Hits InterMune Exec With Insider Trading Suit
• Life Sciences Groups Assail SF's Drug 'Take-Back' Plan
• 9th Circ. Revives Amgen ERISA Suit After High Court Remand
• Anemia Biotech FibroGen Readies For $124M IPO
• Rhythm Drops $86M IPO Plan After Actavis Deal
• Convicted Ex-Pfizer Manager Won't Testify In Off-Label Suit
• 11th Circ. Sends Trade Secret Dispute To Arbitration
• Jones Day Adds Ex-Womble Carlyle Tobacco Litigator
• New Guidelines Suggest A Friendlier European Patent Office
• GSK, Apexus Escape Drug Discount Antitrust Suit
• Law360 Names Most Feared Plaintiffs Firms Of 2014
• Apotex Wants Sanctions In Generic-Lipitor Labeling Suit
• Hospitals Decry Genentech's Cancer Drug Delivery Overhaul
• Biomet Pays $6M To End FCA Suit Over Bone-Growth Device
• Sens. Say Adding Ebola To FDA Program May Hasten Vaccine
• Teva Tells 3rd Circ. Other Rulings Back Lamictal Dismissal
• Fed. Circ. Won't Revive Expired Harvard Mice-Testing Patent
• Ex-Patent Rights Holders Want $20M Skin Drug Suit Revived
• HHS Looks To Existing Procurement Tool For Ebola Drugs
• Vinson & Elkins Nabs Litigators From Fenwick, Morgan Lewis
• FDA's Drug Risk Promo Proposal Slammed By All Sides
• Pa. Superior Court Urged To Nix $15M In Topamax Verdicts
• Cooley Leads Breast Implant Maker Sientra In $75M IPO
• Gov't Contractor Indicted For Alleged $116M Drug Return Plot
• Biosig Says Patent Is Valid Under New High Court Standard
• Minority Powerbrokers Q&A: Marshall Gerstein's Rin-Laures
• A Look At The First Ebola-Related Securities Lawsuit
• SEC Probes CMS In Stock Info Leak Investigation
• Allergan Says Ackman's Valeant Vote Would 'Gut' Protections
• Columbia Agrees To $9M Deal In Federal AIDS Grant FCA Row
• Actos Ruling Sets Up Appellate Clash Over Punitives Ceiling
• Illumina DNA Sequencing Patent Nixed In AIA Review
• Medicines Co. Beats Mylan In Generic-Angiomax Fight
• Amgen Spurns Breakup, Dusts Off $2B Buyback Plan
• Pfizer Says Lipitor Buyers Shouldn't Get To Redo Antitrust Suit
• Titan Of The Plaintiffs Bar: Mark Rifkin
• Kirkland Reps GTCR In Strategic Devicor Exit
• Covington Snags Ex-Norton Rose Fulbright Antitrust Chief
• Pfizer Keeps Market Guessing On M&A Moves As Earnings Rise
• A Close Look At The First 2 Post-Grant Review Petitions
• Acorda Ditches Apotex's Zanaflex False Ad Suit
• Fed. Circ. May Fill In Blanks On New Indefiniteness Rule
• $9B Takeda, Eli Lilly Actos Damages Slashed To $37M
• Fera's Injunction Claim Axed In $100M Trade Secret Suit
• Calif. Med Tech Co. Sets Terms For $100M IPO
• Biotech Co. Misled Investors About Role In Ebola Drug: Suit
• Looking At Lanham Act Claims Against Drug Cos. Post-Pom
• PE-Backed INC Research Aims To Raise Up To $150M In IPO
• Fujifilm Scoops Up Vaccine Maker As Ebola Crisis Worsens
• Allergan Decries Ackman's Smear Campaign Allegations
• Use Social Media For Legal Service Only As A Last Resort
• Valeant Could Hike Allergan Offer To $200-Plus Per Share
• Edwards IP Team May Join Mintz Levin Due To Merger
• Liberty Medical Strikes Deal Trimming $160M Medicare Claim
• NJ Diagnostic Co. Takes Merck Licensing Row To High Court
• US Urged To Pursue Contact Lens Antitrust Case
• Verinata's Fetal Test Patent Survives AIA Review On All Claims
• Nature's Bounty Duped Elderly Into Buying Gingko Biloba: Suit
• Hikma Gets FDA Warning After Portugal Facility Review
• 5 Ditch IPO Plans This Week As Markets Continue Volatility
• 4 Things To Watch As FDA Flexes New Inspection Powers
• Eli Lilly Gets AIA Reviews Of Institute's Fibrosis Patent
• Ex-BNY Mellon Manager Admits Tipping Scheme
• Shire Looks To Sink $1.5B AbbVie Termination Fee Into M&A
• Coherus Seeks IPO Raising $108.6M To Fund New Drugs
• New Restrictions On Int'l Trade In Genetic Resources
• Surprise Verdict In Hip Implant Trial Gives J&J The Edge
• Pfizer Unveils Mammoth $11B Buyback Program
• FDA Should Nix Drug Risk Proposal, Advocacy Group Says
• Teva Sues Chicago To Block Painkiller FOIA Disclosure
• San Francisco Reintroduces Drug 'Take-Back' Proposal
• Bankrupt Vitamin Maker Natrol Gets Nod For Nov. Auction
• FDA Clarifies Oversight Exception For Stem Cell Procedures
• Jury Clears J&J In 1st Bellwether Over Pinnacle Hip Implant
• Scientists Can't Shake $10M Gov't Contract Fraud Charges
• Pfizer's Cancer Drug Patent Withstands Mylan Challenge
• Grunenthal Dodges Thalidomide Suit In Spain
• Lupin, Amneal Lose Bid To Reverse Birth Control IP Ruling
• Bard Says Expert Can't Switch Sides In Pelvic Mesh MDL
• Reed Smith Hatches Global Ebola Task Force
• Biotech IPO Market Hits Turbulence As Several Price Low
• Deals Rumor Mill: Apollo Global, Advent, Sterigenics
• Ropes & Gray Sued By Drugmaker Over Patent Filing Blunder
• Effexor Buyers Want Another Chance In Antitrust Suit
• Glaxo Eyes IPO For HIV Unit As Part Of Restructuring Plan
• Nexium Jury Hears From Walgreen Exec On Generics
• ITC Agrees To Review Construction Of Sleep-Aid Patents
• OIG Remains Focused On Pharmaceutical Copayment Coupons
• Mylan Signals $5.3B Abbott Inversion On Track After Tweaks
• New Jurisdictional Issues When Moving To Quash A Subpoena
• Actavis Wins Bid To Keep Parts Of Antitrust Suit Under Seal
• DePuy Hip Implant Bellwether Trial Heads To Jurors In Texas
• OIG Finds Flaws In FDA's Cybersecurity Protections
• Pfizer Fights 'Do-Over' Of Plaintiff Experts In Zoloft MDL
• Viamet Gets $60M In Private Financing After Nixing IPO
• Deals Rumor Mill: Actavis, Siemens, Yahoo
• Titan Of The Plaintiffs Bar: Mark Lanier
• Senate Shake-Up Would Breathe New Life Into ACA Battles
• Nexium Jury Told Drug Cos. Wheeled-And-Dealed With Patent
• Nexium Pay-For-Delay Jury Told Size Of Settlement Is Key
• Molecular Partners Hits Brakes On IPO In Shaky Market
• Avandia User's Warranty Violation Suit Flops In 3rd Circ.
• FDA Finalizes Stance On Obstructed Pharma Inspections
• Special Master To Helm Walgreen Fee Fight In Pfizer MDL
• AbbVie Launches $5B Buyback After Failed Deal
• Ackman Says Allergan CEO Oversaw Valeant Smear Campaign
• GSK Bribery Conviction Signals Increased Risks In China
• Full Fed. Circ. Won't Review BMS Hepatitis Drug Patent Ruling
• Tech Giants Attack ITC's Patent Ruling On Digital Data
• TPP Catches Flak From Aussie Pols As Talks Forge Ahead
• Firsthand Knowledge Needed To Clear FCA Bar, 3rd Circ. Rules
• Device Makers Find Little Clarity In FDA Recall Guidance
• Atty Dodges Sanctions For 'Manic' Behavior At Fosamax Trial
• GE Can't Escape $5M Omniscan Verdict, 6th Circ. Says
• Pashman Stein Wins Rehearing Of Nostrum Fee Battle
• Amgen, CVS Units Hit With Suit Over Arthritis Drug Shipping
• Deals Rumor Mill: Adidas, Allergan, Sigma-Tau
• Dr. Reddy's Settles On Eve Of Nexium Pay-For-Delay Trial
• Cooley Steers Breast Implant Maker Sientra's IPO Plans
• Strong Valeant Earnings Buoy Talk Of Heftier Allergan Bid
• Fed. Circ. Slams Fee-Shifting Requirement In Pfizer IP Suit
• Random Selection Is Best For MDL Bellwether Trials
• Shire Loses CFO Following Failed $55B AbbVie Merger
• Takeda Urges Pa. Judge To Strike $2M Actos Cancer Verdict
• Actavis Aims To Shed Some Manhattan RE After Forest Buy
• Chattem Fights Class Cert. In Mouthwash Class Action
• Lawmakers Urge HHS To Combat Rising Generic-Drug Prices
• 5 IPOs Aim To Draw $450M In Coming Week
• Lannett Seeks Sanctions After Price-Fixing Suit Dropped
• First Actos Bladder Cancer Suit In W.Va. Goes To Trial
• CMS Launches New Open Payments Search Tool
• Taxation With Representation: Andrews Kurth, Jones Day
• 3rd Circ. Revives Genaera Investor Suit Over Asset Sales
• Covidien Earns Injunction Against J&J Unit's Ultrasonic Shears
• Hi-Tech Execs Want Out Of Jail After Recall
• Enviros Ask FDA To Ban 2 Food Packaging Chemicals
• Post-Firing Evidence Can Be A Potent Limit On Bias Damages
• What Litigators Can Learn From Novelists
• WikiLeaks Sparks Outcry With Release Of TPP Draft IP Text
• Ex-Siemens Patent Atty Indicted Over $2.5M Kickbacks Fraud
• Advocates Urge Fed. Circ. To Curtail ITC Digital Data Ruling
• GSK Dodges Claims Over Thalidomide Birth Defects
• FDA Naming Delay Cut Short Exclusivity, Drugmaker Says
• Deals Rumor Mill: PolyOne, Allergan, Wizz Air Holdings
• Kirkland Snags Lead BP Deepwater Litigation Trial Counsel
• J&J's Ethicon Fights $3M Verdict In Pelvic Mesh Trial
• Wilson Sonsini Grows In Delaware With Wilmington Office
• $55B AbbVie Deal Collapse Boosts Anti-Inversion Campaign
• Becton, Bard Trade Secrets Thief Gets 18 Months
• 3 Things To Watch Out For In Nexium Pay-For-Delay Trial
• One Biopharm Nixes IPO Plans As Second Makes Rocky Debut
• Ranbaxy To Pay $40M To Settle Texas Medicaid Fraud Case
• A-Rod's Purported Supplier Pleads Guilty To Drug Charges
• The 4 Hottest Sectors For IPOs Right Now
• The Learned Intermediary Doctrine: A Historical Review
• AbbVie Scraps $55B Shire Inversion After Treasury Crackdown
• If High Court Reverses Teva, Litigation Costs May Increase
• High Court Appears Split On Claim Construction Deference
• Investors Knock SAC's Bid To Cut Racketeering Claims
• Generic Drug Cos. Seek Federal Preemption Of Reglan Claims
• Deals Rumor Mill: ConvaTec, Vodafone, French Gov't
• Organon To Pay $31 Million Over FCA Medicaid Allegations
• PTAB To Review Claims In Novartis' Dementia Patch Patents
• Forward Pharma Raises $220M In Year's Largest Biotech IPO
• Assessing FDA Powers After A Failed 510(k) Rescinding
• AbbVie Backpedals On Landmark Inversion After Rule Tweaks
• NJ Tax Court Won't Revisit $3M Elan Assessment
• 9th Circ. Critical In Growing Class Ascertainability Fight
• Ex-Merck Analyst Charged With Insider Trading
• Supreme Court Passes On Medtronic's Noninfringement Win
• Deals Rumor Mill: Sysco, GlaxoSmithKline, Providence Equity
• ACA Spurs Feds To Rethink Anti-Kickback Policies
• Life Sciences M&A Keeps Rolling After Inversion Clampdown
• Biogenesis Co-Conspirator Pleads Guilty To MLB Doping
• Durata Investor Sues To Halt $675M Actavis Deal
• FDA Axes Controversial Plan On Med Device Safety Reports
• A Convergence Of Antitrust, Anti-Graft Enforcement In China
• Information Governance: A Missed Opportunity For Lawyers
• Med Tech Firm Steris Inks 1st Big Inversion Since Crackdown
• No Question Actavis Goes Beyond Cash, FTC's Wright Says
• AstraZeneca Facing Suit In Texas Over Seroquel Marketing
• Drug Company, Ex-Consultant Spar Over Noncompete Deal
• Off-Label Claims In Cephalon FCA Suits Trimmed By Judge
• FDA Approves New Gilead Hepatitis C Combination Drug
• Deals Rumor Mill: Actavis, Reliance Industries, Old Mutual
• Amberen Maker Blocked From Suing Class Action Plaintiff
• 2nd Circ. Weighs Sanction Doled To Bombastic Fosamax Atty
• Taxation With Representation: Fried Frank, Wachtell, Sullivan
• High Court Could Make It Harder To Reverse Patent Rulings
• CareMed Forks Over $10M To Settle FCA Phone Fraud Suit
• CAFA Removal Procedure At Center Stage In Dart Cherokee
• SEC Weighs Victims' Fund From $602M SAC Settlement
• J&J Unit Escapes Suit Over Birth Control Patch Clotting Risks
• Covington Atty Beats Back Trial Subpoena In Nexium MDL
• 2nd Circ. OKs Fujifilm's Post-Firing Evidence In Bias Suit
• NJ Court Nixes Jurisdiction Over Foreign Co. In Injury Suit
• PhRMA Launches New Suit Over 340B Orphan Drug Rule
• 3rd Circ. Sends Paxil Birth Defect Suit Back To Pa.
• ITC Asked to Reconsider Construction Of Sleep-Aid Patents
• Feds Challenge Ex-Orioles Player's Personal Benefit Defense
• Arnold & Porter in NY Gains Sheppard Mullin IP Partner
• BMS, Otsuka Say Abilify FCA Claims Don't Stick
• Auxilium Scraps Inversion Plan In Favor Of $2.6B Endo Offer
• FDA Takes Another Step Toward Regulating LDTs
• 4th Circ. Sets High Court FCA Agenda For 2014-15 Term
• Effexor Ruling Gives Plaintiffs Path Against No-AG Deals
• Calif. Judge Pares Par's False-Ad Suit, Citing Pom
• IBM, Oracle Prod Congress To Clarify FDA's Health IT Powers
• Deals Rumor Mill: Valeant, Shell, PT Pertamina
• Merck Can't Dodge $250M Sex Bias Class Action
• DLA Piper Snags Dentons Litigation Partner In Los Angeles
• Full Fed. Circ. Asked To Restore Apotex Patent
• Headhunting Firm Accuses Novartis Of $578K Breach
• J&J Pelvic Mesh Plaintiffs Want Cases Kept In Philly
• TTAB Axes Philips' Bid To Register Toothbrush Design Mark
• Is The Food GRAS Rule Silently Being Rewritten?
• A Primer On 'Bad Faith' In Federal Removal Jurisdiction
• Medtronic Infuse Injury Suit Revived By Md. Appeals Court
• Justices Question Their Powers In Class Action Removal Row
• GSK Investigating Corruption Allegations In UAE
• Pashman Stein Fights NJ Decision Freeing Nostrum From Fees
• Deals Rumor Mill: Swisscom, Waterland, Actavis
• Effexor Judge Says No-AG Deals Can Count As Payment
• Kimberly-Clark Ups Repurchase Goal To $2B After Spinoff
• Drugmakers Beat Doc Request In Diabetes Drug MDL
• Medtronic Pushes Tax Court For $581M Refund In IP Dispute
• 11th Circ. Pushback On Medical Guideline Litigation
• The State Of Umbrella Damages Under Calif. Antitrust Law
• King & Spalding Hires FTC Official For Antitrust Group In DC
• Sanofi Says It Revealed Overseas Bribery Claims To US
• Ex-Medtronic Worker Urges 9th Circ. To Revive OT Class
• Fed. Circ. Dismisses Lupin's Birth Control Cross Appeal
• Ex-Stiefel Exec Tells 11th Circ. His Stock Suit Was Timely
• Jurisdiction Bars 118 Philly Pelvic Mesh Suits, J&J Says
• Hi-Tech Execs To Remain Jailed Until Recall Is Complete
• Edwards Wildman Sees More London Exits Amid Merger Talks
• Covington Atty Says No Basis For Nexium Trial Subpoena
• High Court Won't Hear Omnicare Whistleblower's FCA Case
• Ex-Oriole Calls Feds' Insider Trading Indictment Flawed
• Michael J. Fox Foundation Sues Lab Over Spoiled Specimens
• $20M Knee Injury Dispute Could Rejigger Pa. Tort Law
• Bayer Rips Feds' Contempt Bid In Probiotics Promo Fight
• Herbalife Taps Ex-FTC Official As Global Compliance VP
• Actavis Tells High Court To Nix Lialda Patent Appeal
• Deal-Hungry Actavis Inks $675M Deal To Boost Disease Biz
• In-House Insights From KBR General Counsel Andrew Farley
• Takeaways From Chancery's Cornerstone Decision
• Skadden Steers Becton Dickinson To $12B CareFusion Buy
• Stryker Asks Justices To Hear Bed Patent Suit, Pending Teva
• Calif. Biotech Co. Dermira Debuts With $125M IPO
• Taxation With Representation: Cleary, Skadden, Baker
• Judge Says Actavis Not Limited To Cash Deals
• 4 Accutane Suits Against Roche Filed Too Late, Judge Rules
• Jury Hits Takeda With $2M In Damages In Philly Actos Case
• Deals Rumor Mill: Yahoo, Platform Specialty, Kellogg
• EU Opens In-Depth Probe Into $13B Zimmer-Biomet Deal
• Feds Target NJ Co. Over Tainted Ultrasound Gels
• Fed. Circ. To Eye Gene Patent Ruling's Reach In Myriad Case
• Nexium Buyers Point To Dow Ruling To Support Class Cert.
• Allergan's Hope For Rival Deal Dims Amid Investor Outcry
• CMS Payment Data Website May Stop Some FCA Claims
• Drug Labels Can Provide 'Specific Intent' For Inducement
• New Inversion Rules Force Medtronic Into Costlier Financing
• $2.7B Salix Inversion 1st Casualty Of Government Crackdown
• Covington Atty Takes Fire For Bucking Nexium Trial Subpoena
• Boston Scientific Hit With $34.6M Pelvic Mesh Judgment
• Sandoz Targets Chiesi Cardene Patents For PTAB Review
• Philly Jury Urged To Find Takeda Cancer Warnings Fell Short
• Lab Products Co. VWR Raises $536M In IPO
• Tyson Stops Use Of Antibiotics At Chicken Hatcheries
• ACA Payment Reporting Threshold Fuels Pharma Headaches
• Duane Morris Adds Corporate Star To Philly Office
• Stryker Can't Shake Claims Over Knee Implant Allergies
• FDA Finalizes Cybersecurity Guidance For Medical Devices
• Liberty Medical Unveils Plan For $47M Stalking Horse Sale
• BMS, Sanofi Lose Remand Challenge In Plavix MDL
• 7th Circ. Asked To Revive Ciba Contact Lens Injury Suit
• FDA Warns Hospira Over Injectable Drug Violations
• Philips Slammed With $467M Verdict In Masimo Patent Trial
• AbbVie Can't Keep AndroGel Death Suit Out Of State Court
• Takeda Shared Actos Cancer Data, Ex-FDA Official Testifies
• Blank Rome Adds Generic Drugs Pro From Reed Smith
• Covidien Unit Escapes FCA Suit Over Off-Label Marketing
• 1 Mammoth Deal Helps 2 Firms Dominate September M&A
• 11th Circ. Weighs In On Duty To Disclose Merger Talks